| 1 | Abatacept, rituximab or tocilizumab | [3] AbataceptAbatacept, Rituximab,
 Tocilizumab
 | [3] D02596D02596
                
             (Name: Tocilizumab), D02994
                
            ,
 D03203
 | [4] CD80CD80, CD86,
 IL6R,
 MS4A1 💬
 | [24] Allograft rejectionAllograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 2 | Adalimuab, Etanercept, Tocilizumab, or Abatacept | [3] AbataceptAbatacept, Etanercept,
 Tocilizumab
 | [3] D00742D00742
                
            , D02596
                
             (Name: Tocilizumab),
 D03203
 | [5] CD80CD80, CD86,
 IL6R,
 LTA,
 TNF 💬
 | [79] AGE-RAGE signaling pathway in diabetic complicationsAGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, Autoimmune thyroid disease, C-type lectin receptor signaling pathway, Cell adhesion molecules, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Toxoplasmosis, Transcriptional misregulation in cancer, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | [1] 4646 | 
| 3 | Corticoids+ tocilizumab 8mg/Kg/4 weeks | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4141 | 
| 4 | Decrease Tocilizumab, Abatacept | [2] AbataceptAbatacept, Tocilizumab
 | [2] D02596D02596
                
             (Name: Tocilizumab), D03203
 | [3] CD80CD80, CD86,
 IL6R 💬
 | [24] Allograft rejectionAllograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 5 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab | [4] AbataceptAbatacept, Rituximab,
 Sarilumab,
 Tocilizumab
 | [4] D02596D02596
                
             (Name: Tocilizumab), D02994
                
            ,
 D03203
                
            ,
 D10161
 | [4] CD80CD80, CD86,
 IL6R,
 MS4A1 💬
 | [24] Allograft rejectionAllograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 6 | INN-Tocilizumab | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 266266 | 
| 7 | Intra-articular Tocilizumab | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 8 | MRA (Tocilizumab) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 4646, 107 | 
| 9 | MRA(Tocilizumab) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 4646, 107 | 
| 10 | RoActemra/Actemra (tocilizumab) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 107107 | 
| 11 | Subcutaneous tocilizumab | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 12 | Subcutaneous tocilizumab 162mg/biweekly | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 13 | Tocilizumab | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [21] 22, 11, 13, 40, 41, 42, 43, 44, 46, 49, 50, 51, 53, 54, 55, 56, 86, 107, 266, 271, 331 | 
| 14 | Tocilizumab (Actemra or RoActemra) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 15 | Tocilizumab (Actemra) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 16 | Tocilizumab (Actemra®) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 17 | Tocilizumab (MRA-SC) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4040 | 
| 18 | Tocilizumab (TCZ) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 4646, 56 | 
| 19 | Tocilizumab + Glucocorticoids (GCs) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4141 | 
| 20 | Tocilizumab + methotrexate(MTX) | [2] MethotrexateMethotrexate, Tocilizumab
 | [3] D00142D00142
                
            , D02115
                
            ,
 D02596
                
             (Name: Tocilizumab)
 | [3] DHFRDHFR, DHFR2,
 IL6R 💬
 | [17] Antifolate resistanceAntifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 21 | Tocilizumab 162 mg | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 22 | Tocilizumab 162mg/0.9ml jeringa SC | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 23 | Tocilizumab 162mg/0.9ml SC PFS SC | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 24 | Tocilizumab 162mg/0.9ml syringe SC | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 25 | Tocilizumab [RoActemra/Actemra] | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [4] 4646, 51, 107, 331 | 
| 26 | Tocilizumab [RoActemra] | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 27 | Tocilizumab and IV steroids combination | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4141 | 
| 28 | Tocilizumab Infusion RoAcemtra (EU) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 266266 | 
| 29 | Tocilizumab Injectable Product | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 1111 | 
| 30 | Tocilizumab Injection | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 1313 | 
| 31 | Tocilizumab Injection 8mg/kg | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 32 | Tocilizumab IV | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 33 | Tocilizumab plus methotrexate | [2] MethotrexateMethotrexate, Tocilizumab
 | [3] D00142D00142
                
            , D02115
                
            ,
 D02596
                
             (Name: Tocilizumab)
 | [3] DHFRDHFR, DHFR2,
 IL6R 💬
 | [17] Antifolate resistanceAntifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 34 | Tocilizumab Prefilled Syringe | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 4141, 46 | 
| 35 | Tocilizumab Roche | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [2] 4646, 107 | 
| 36 | TOCILIZUMAB SC | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [3] 4141, 46, 107 | 
| 37 | Tocilizumab SC 162 mg/0.9 ml disposable auto-injector (AI) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 38 | Tocilizumab SC 162 mg/0.9 ml pre-filled syringe with safety device (PFS) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 39 | Tocilizumab SC 162 mg/0.9 ml prefilled syringe with safety device (PFS) | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 5151 | 
| 40 | Tocilizumab treatment | [1] TocilizumabTocilizumab | [1] D02596D02596
                
             (Name: Tocilizumab) | [1] IL6RIL6R 💬 | [12] Coronavirus disease - COVID-19Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4141 | 
| 41 | Tocilizumab+Methotrexate(MTX) | [2] MethotrexateMethotrexate, Tocilizumab
 | [3] D00142D00142
                
            , D02115
                
            ,
 D02596
                
             (Name: Tocilizumab)
 | [3] DHFRDHFR, DHFR2,
 IL6R 💬
 | [17] Antifolate resistanceAntifolate resistance, Biosynthesis of cofactors, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Folate biosynthesis, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Metabolic pathways, Non-alcoholic fatty liver disease, One carbon pool by folate, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 42 | Tocilizumab, Abatacept | [2] AbataceptAbatacept, Tocilizumab
 | [2] D02596D02596
                
             (Name: Tocilizumab), D03203
 | [3] CD80CD80, CD86,
 IL6R 💬
 | [24] Allograft rejectionAllograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor 💬 | [1] 4646 | 
| 43 | Tocilizumabum | - | - | - | - | [1] 4646 |